Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01348607 · OUTCOME

Average Daytime Napping Minutes in a Week

Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy · Source last updated 2014-02-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
minutes
Interval / dispersion
Standard Deviation
Time frame
29 days

What was measured

Outcome measure was the total of daytime napping minutes in a week as assessed by participant sleep diaries

Groups in this outcome

Arm I - Methylphenidate Hydrochloride

Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.

Arm II -Modafinil

Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.

Arm III Placebo

Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I - Methylphenidate Hydrochloride1
Arm II -Modafinil0
Arm III Placebo0

Reported measurements

Source class 1
Values in minutes · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Arm I - Methylphenidate Hydrochloride36.7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        36.7
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    units
    Participants
description
Outcome measure was the total of daytime napping minutes in a week as assessed by participant sleep diaries
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
    id
    OG000
    title
    Arm I - Methylphenidate Hydrochloride
  2. description
    Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
    id
    OG001
    title
    Arm II -Modafinil
  3. description
    Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
    id
    OG002
    title
    Arm III Placebo
param Type
MEAN
reporting Status
POSTED
time Frame
29 days
title
Average Daytime Napping Minutes in a Week
type
PRIMARY
unit Of Measure
minutes

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice